Talks in Washington D.C. of impeachment and obstruction of justice rattled investors to send the markets plummeting to a sharply lower close with the Dow crashing 372 points to 20,606. Nasdaq collapsed 158 points to 6,011.

On the upside

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that patients in the ENCORE 601 non-small cell lung cancer trial will advance to the second stage of the Phase 2 trial.

Pulmatrix (Nasdaq: PULM) chief financial officer Bill Duke said that the company's PUR1900 inhaled therapy for treating fungal infections has the potential to be a blockbuster.

The Patent Trial and Appeal Board ruled in favor of Coherus BioSciences' (Nasdaq: CHRS) petitions for Inter Partes Review of AbbVie's U.S. Patent 8,889,135.

On the downside

Bebe (Nasdaq: BEBE) will have to make between $60 to $65 million in lease termination payments.

Roth Capital downgraded Plug Power (Nasdaq: PLUG) from a Neutral rating to a Sell rating and cut its price target from $2.25 to $1.30.

Shares of Forterra (Nasdaq: FRTA) fell for the fourth day.

The broader S&P 500 skidded 43 points to 2,357. Bitcoin surged $77 to $1770.